You are here: Industry Insights > ARDS

News List

Enzychem Files IND for Phase 2 Study of EC-18 in Preventing ARDS Due to COVID-19 Pneumonia americanpharmaceuticalreview
July 22, 2020
Enzychem Lifesciences has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a Phase 2 clinical trial of EC-18 as a preventative therapeutic against Acute Respiratory Disease Syndrome (ARDS) due to ...
Immune Regulation teams with DynPort on COVID-19 drug pharmatimes
July 07, 2020
US and UK-based clinical stage biotech Immune Regulation has signed a deal with DynPort Vaccine Company to jointly evaluate the potential of the former's ILR201104 to treat COVID-19 related Acute Respiratory Distress Syndrome (ARDS) in US clinical trials.
EUSA Pharma bags US approval for COVID-19 trial pharmatimes
July 03, 2020
US regulators have issued a green light for a Phase III clinical trial testing EUSA Pharma's for patients seriously ill with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).
SFX‐01 to enter Phase II/III trials to test efficacy against COVID-19 symptoms europeanpharmaceuticalreview
June 19, 2020
The drug candidate SFX-01 is set to be studied in Phase II/III trials to test its efficacy at treating acute respiratory distress syndrome (ARDS), a complication of COVID‐19.
Evgen's SFX-01 selected for COVID-19 trial pharmatimes
June 18, 2020
Evgen Pharma's lead candidate SFX-01 has been selected for evaluation in a randomised Phase II/III trial, to be sponsored by the University of Dundee, which aims to investigate its potential as a treatment for COVID-19.
Trial for new ibuprofen formulation as COVID-19 treatment launched in UK europeanpharmaceuticalreview
June 16, 2020
A unique formulation of ibuprofen is being tested as a treatment for severe acute respiratory distress syndrome (ARDS), a symptom of COVID-19.
Relief Therapeutics, NeuroRx Begin RLF-100 Study for COVID-19 Associated ARDS americanpharmaceuticalreview
June 10, 2020
Relief Therapeutics and its U.S. partner, NeuroRx, announced treatment of the first patients with RLF-100 at the University of Miami Miller School of Medicine, FL.
Cellenkos Announces FDA Clearance for Trial of CK0802 for COVID-19 ARDS americanpharmaceuticalreview
June 08, 2020
Cellenkos announced the US Food & Drug Administration (FDA) has cleared the way to initiate a Phase 1 clinical trial of CK0802 (Cryopreserved Cord Blood Derived T-Regulatory Cells) for treatment of COVID-19 associated acute respiratory distress syndrome.
Anti-TNF therapies could treat patients with COVID-19-related ARDS expresspharma
June 08, 2020
This would reduce COVID-19 mortality, as about 17 of COVID-19 patients develop ARDS, states GlobalData.
AgeX Therapeutics, ImStem Biotechnology sign non-binding letter of intent regarding investigational pharmaceutical-business-review
June 05, 2020
AgeX Therapeutics and ImStem Biotechnology, Inc. announced their signing of a non-binding letter of intent for ImStem to obtain from AgeX a non-exclusive license to use AgeX’s embryonic stem cell line ESI 053 to use AgeX’s embryonic stem cell ...

Previous page 1 2 3 4 5 6 7 Next page